QuiaPEG Pharmaceuticals Holding AB Cash Flow Conversion Efficiency

Latest as of June 2025: -0.115x

QuiaPEG Pharmaceuticals Holding AB cash flow conversion efficiency. Based on the latest financial reports, QuiaPEG Pharmaceuticals Holding AB (QUIA) has a cash flow conversion efficiency ratio of -0.115x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-747.00K ≈ $-80.39K USD) by net assets (Skr6.47 Million ≈ $696.28K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of QuiaPEG Pharmaceuticals Holding AB (2008–2024)

Cash flow conversion efficiency of QuiaPEG Pharmaceuticals Holding AB from 2008 to 2024. This chart illustrates how QuiaPEG Pharmaceuticals Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View QUIA live share price for real-time trading data and today's change.

QuiaPEG Pharmaceuticals Holding AB Cash Flow Conversion Ratio Explained

QuiaPEG Pharmaceuticals Holding AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

QuiaPEG Pharmaceuticals Holding AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of QuiaPEG Pharmaceuticals Holding AB ranked by their cash flow conversion efficiency. Also see QuiaPEG Pharmaceuticals Holding AB stock valuation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
RTC Group plc
LSE:RTC
0.106x
Orcadian Energy PLC
LSE:ORCA
-0.093x
First Class Metals PLC
LSE:FCM
-0.361x
Essensys PLC
LSE:ESYS
0.045x
SCANDION ONC. DK-0735
F:8VY
N/A
Croma Security Solutions Group Plc
LSE:CSSG
0.003x
DSW Capital PLC
LSE:DSW
0.184x
Akoustis Technologies, Inc.
NASDAQ:AKTSQ
0.187x

Annual Cash Flow Conversion Efficiency for QuiaPEG Pharmaceuticals Holding AB (2008–2024)

The table below shows the annual cash flow conversion efficiency of QuiaPEG Pharmaceuticals Holding AB from 2008 to 2024. Review QUIA free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Skr16.35 Million
≈ $1.76 Million
Skr-10.17 Million
≈ $-1.09 Million
-0.622x +7.61%
2023-12-31 Skr15.25 Million
≈ $1.64 Million
Skr-10.27 Million
≈ $-1.10 Million
-0.673x +91.07%
2022-12-31 Skr2.41 Million
≈ $259.57K
Skr-18.18 Million
≈ $-1.96 Million
-7.536x +99.18%
2021-12-31 Skr22.00K
≈ $2.37K
Skr-20.11 Million
≈ $-2.16 Million
-914.091x -129.27%
2020-12-31 Skr71.00K
≈ $7.64K
Skr-28.31 Million
≈ $-3.05 Million
-398.704x -22715.75%
2019-12-31 Skr-8.57 Million
≈ $-922.48K
Skr-15.11 Million
≈ $-1.63 Million
1.763x +109.25%
2018-12-31 Skr545.00K
≈ $58.65K
Skr-10.39 Million
≈ $-1.12 Million
-19.068x -1007.89%
2017-12-31 Skr6.04 Million
≈ $649.79K
Skr-10.39 Million
≈ $-1.12 Million
-1.721x -1865.23%
2016-12-31 Skr18.44 Million
≈ $1.98 Million
Skr1.80 Million
≈ $193.49K
0.098x +38.56%
2015-12-31 Skr6.92 Million
≈ $744.81K
Skr487.00K
≈ $52.41K
0.070x -69.52%
2014-12-31 Skr6.44 Million
≈ $693.26K
Skr1.49 Million
≈ $160.02K
0.231x -24.20%
2013-12-31 Skr7.24 Million
≈ $779.57K
Skr2.21 Million
≈ $237.40K
0.305x +156.89%
2012-12-31 Skr9.73 Million
≈ $1.05 Million
Skr-5.21 Million
≈ $-560.57K
-0.535x -393.31%
2011-12-31 Skr13.98 Million
≈ $1.50 Million
Skr2.55 Million
≈ $274.53K
0.183x +18.41%
2010-12-31 Skr17.17 Million
≈ $1.85 Million
Skr2.65 Million
≈ $284.75K
0.154x +50.57%
2009-12-31 Skr17.82 Million
≈ $1.92 Million
Skr1.82 Million
≈ $196.29K
0.102x +92.50%
2008-12-31 Skr17.98 Million
≈ $1.93 Million
Skr956.00K
≈ $102.88K
0.053x --

About QuiaPEG Pharmaceuticals Holding AB

ST:QUIA Sweden Biotechnology
Market Cap
$141.00K
Skr1.31 Million SEK
Market Cap Rank
#31436 Global
#738 in Sweden
Share Price
Skr0.00
Change (1 day)
-16.67%
52-Week Range
Skr0.00 - Skr0.00
All Time High
Skr464.25
About

Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as… Read more